• O Udruženju

Welcome

Forgot password?

Not a member? Join today

Logo
  • Početna
  • Limfom
    • Hronična limfocitna leukemija
    • Non hočkinski limfom
    • Hočkinski limfom
    • Koji je tvoj podtip?
  • Živeti sa limfomom
    • Korisni saveti
    • Ishrana hematoloških bolesnika
  • COVID-19
  • Resursi
    • Video edukacija
    • Brošure
    • Newsletter
  • Početna
  • Limfom
    • Hronična limfocitna leukemija
    • Non hočkinski limfom
    • Hočkinski limfom
    • Koji je tvoj podtip?
  • Živeti sa limfomom
    • Korisni saveti
    • Ishrana hematoloških bolesnika
  • COVID-19
  • Resursi
    • Video edukacija
    • Brošure
    • Newsletter

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

15 Mar 2019
  • administrator
  • Hronična limfocitna leukemija

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

PURPOSE The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixedduration venetoclax-rituximab compared with

LIPA

Radnim danima od 10h-14h

060 022 2317

065 331 3883

e-mail: lipaserbia@gmail.com

www.lipa.org.rs

www.bloodcancer101.org.rs

www.podelizabuducnost.org.rs

PRIJATELJI UDRUŽENJA